Equities research analysts at Ladenburg Thalmann lowered their price target on shares of AMAG Pharmaceuticals (NASDAQ: AMAG) from $25.00 to $23.00 in a research note issued to investors on Monday, Analyst Ratings Network.com reports. Ladenburg Thalmann’s price objective suggests a potential upside of 15.87% from the stock’s previous close.
Shares of AMAG Pharmaceuticals (NASDAQ: AMAG) traded up 0.49% during mid-day trading on Monday, hitting $20.50. AMAG Pharmaceuticals has a one year low of $12.43 and a one year high of $23.98. The stock’s 50-day moving average is currently $21.49. The company’s market cap is $442.3 million.
AMAG Pharmaceuticals (NASDAQ: AMAG) last posted its quarterly earnings results on Tuesday, April 23rd. The company reported ($0.18) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.20) by $0.02. The company had revenue of $17.90 million for the quarter, compared to the consensus estimate of $17.99 million. During the same quarter last year, the company posted ($0.58) earnings per share. AMAG Pharmaceuticals’s revenue was up 15.5% compared to the same quarter last year. Analysts expect that AMAG Pharmaceuticals will post $-0.63 EPS for the current fiscal year.
Separately, analysts at Jefferies Group raised their price target on shares of AMAG Pharmaceuticals from $12.00 to $14.00 in a research note to investors on Thursday, April 25th. They now have an “underperform” rating on the stock.
One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $18.20.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (NASDAQ: AMAG).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with Analyst Ratings Network's FREE daily email newsletter.